Abstract
Ampakines are a new group of glutamatergic system modulators with potential benefi cial infl uence on schizophrenic symptomatology what is suggested by outcome of a few published preclinical and clinical studies. Ampakines are agonists of ionotropic AMPA receptor secondarily induce NMDA receptor excitation. Intensifi cation of glutamatergic transmission and normalization of hypoNMDA state is accountable for negative and cognitive symptom improvement. Article describes important properties of AMPA receptor, ampakines and presents results of clinical trials with AMPA agents, mostly concerning CX516.